Followers | 21 |
Posts | 1152 |
Boards Moderated | 3 |
Alias Born | 07/24/2001 |
Saturday, November 24, 2018 9:20:37 PM
I don't claim to know the markets well enough to make arbitrary price predictions on any stock...my predictions are based solely on my read of the stock's candlestick and point and figure charts, which in my 30+ years of experience has served me well... I have found that making investment and trading decisions based on stock charts to be very helpful. Does not mean that my decisions are always right... but over the years, my read of a stock's charts has often helped me avoid making wrong decisions. I believe that reading stock charts is akin to doctors taking electrocardiograms of patients to determine their cardiac health... or lack thereof.
Every stock's daily and hourly trading activity leaves telltale imprints that can be read through charts to determine its immediate health. We all know AMRN stock's longterm health is rock solid...and after Friday's trading activity, it's stock charts paint a picture of very robust health short-term as well (5-10 days)...
Bullish Signs:
1) After the previous trading day's strong 9.5% rise, the stock opened down, tested support, and then made a new weekly high ($19.46) and ended Friday's half day session up 1.2%.
2) The stock stayed strong on a day when most US indices closed in the red.
Now let's read the charts...candlestick first:
In the above chart showing 10 days of trading activity at 60 minute intervals, you can see the stock bumping its head on its resistance line which coincidentally sits just around Friday's intraday high of $19.46!
PnF chart:
As we can see, both the candlestick chart and the PnF chart of AMRN are marching in lockstep and both are clearly highlighting the same breakout point: $19.50 However, the PnF is showing support at $16.50 and the 10 day hourly candlestick is showing support at $18. Of course there is a good reason for this deviation, but it is not important for this current exercise.
Prediction:
Based strictly on my reading of AMRN's charts, I am quite confident that the stock should be able to break through the overhead resistance and print $19.50 as soon as Monday at which point the coast is relatively clear for the stock to reclaim its recent high of $23 and change which of course is the next resistance... Once AMRN prints $24, there is no overhead resistance and the ride to $30 should be pretty quick...There are a number of catalysts that should help, including the Evercore presentation on Tuesday and the weekly scripts numbers, though I won't be surprised if next Friday's numbers show negative or lackluster growth due to an abbreviated week (Thanksgiving holiday).
Barring a total market collapse, I don't expect AMRN stock to see $14 again... and I am quite confident that AMRN stock will hit $30 within 6 weeks even sans news of a European partnership...
But first, let's see how next week pans out... :)
o2w
Recent AMRN News
- Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference • GlobeNewswire Inc. • 05/06/2024 12:00:00 PM
- Amarin Reports First Quarter 2024 Business Update and Financial Results • GlobeNewswire Inc. • 05/01/2024 11:00:00 AM
- Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event • GlobeNewswire Inc. • 04/24/2024 06:00:01 PM
- Amarin Announces Results of Annual General Meeting of Shareholders • GlobeNewswire Inc. • 04/22/2024 12:00:25 PM
- Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024 • GlobeNewswire Inc. • 04/15/2024 12:00:00 PM
- Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24 • GlobeNewswire Inc. • 04/08/2024 12:00:00 PM
- New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • PR Newswire (Canada) • 04/08/2024 10:30:00 AM
- New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • GlobeNewswire Inc. • 04/06/2024 07:30:00 PM
- Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe • GlobeNewswire Inc. • 04/03/2024 12:00:00 PM
- Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo • GlobeNewswire Inc. • 03/25/2024 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 03/04/2024 10:30:53 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/04/2024 01:00:24 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/29/2024 12:06:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 12:05:56 PM
- Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/29/2024 12:00:00 PM
- Amarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February 29, 2024 • GlobeNewswire Inc. • 02/15/2024 01:00:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 02/12/2024 01:00:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:31:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:30:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:30:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:30:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:30:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:30:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/26/2024 12:00:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/24/2024 09:31:21 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM